Advertisement

In response to an Enterohemorrhagic E. coli outbreak that hit Germany beginning in May, Alexion Pharmaceuticals Inc. and Alexion Pharma International Sàrl (APIS) have been approved by German regulators to begin a clinical trial of Soliris as a treatment for Shiga-toxin producing E. coli hemolytic uremic syndrome (STEC-HUS).

More than 35 deaths from EHEC and about 800 confirmed cases of STEC-HUS have been reported in Germany, the Robert Koch Institute indicated. STEC-HUS is considered an extremely rare and potentially fatal complication of EHEC, Alexion reported in a press release.

SOURCE

Advertisement
Advertisement